Connect Biopharma is a San Diego company developing rademikibart, an antibody in trials for asthma and COPD. It last closed at $0.57 on Nov 17, down 11.43% on the day. The average 12-month price target from 6 analysts is $5.33 (+836.5% from the last close), with a high of $7.00 and a low of $4.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell).
Each firm's latest rating on CNTB in the past 90 days
Average 12-month target
$5.33
▲ 836.5% upside
Based on 6 analysts who set a price target on CNTB in the past 90 days. The average target is $5.33, with a high of $7.00 and a low of $4.00, compared with the last close of $0.57.
Low $4.00Avg $5.33High $7.00
Blue marker: last close $0.57
Highest target$7.00
Average target$5.33
Lowest target$4.00
Latest rating changes
Canaccord GenuityMaintained
Nov 17Buy$6
Piper SandlerTarget lowered
Nov 17Buy$7 → $5
Leerink PartnersAssumed coverage
Oct 12Buy$4
BTIGTarget lowered
Sep 30Buy$10 → $5
OppenheimerTarget lowered
Sep 22Buy$8 → $5
Date
Firm
Action
Rating
Price target
Nov 17
Canaccord Genuity
Maintained
Buy
$6
Nov 17
Piper Sandler
Target lowered
Buy
$7 → $5
Oct 12
Leerink Partners
Assumed coverage
Buy
$4
Sep 30
BTIG
Target lowered
Buy
$10 → $5
Sep 22
Oppenheimer
Target lowered
Buy
$8 → $5
Loading…
Technical Analysis
CNTB · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 32% below its 20 day and 74% below its 50 day average. It is 267% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the 52 week low at $0.55, and the nearest resistance the Pivot at $0.59.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 14.2%/day
Key levels
$3.8252 week high+570.2%
$2.09200 day average+266.7%
$1.63100 day average+186.0%
$0.9950 day average+73.7%
$0.87Swing high (Oct 30)+52.6%
$0.7520 day average+31.6%
$0.62Pivot R1+8.8%
$0.59Pivot+3.5%
$0.57Last close
$0.5552 week low−3.5%
$0.53Pivot S1−7.0%
Indicators
RSI (14)
23.96
Oversold below 30
Oversold
MACD
-0.11
Below its signal line
Bearish
Stochastic
13.6
Near the bottom of its range
Oversold
ADX (14)
16.5
No clear trend
Williams %R
-94.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-195.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−26.4%
Change over 10 sessions
Bearish
ATR (14)
$0.08
Typical daily range, 14.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Turning down, oversold
Short trendBearish
Long trendNeutral
MomentumWeak
StretchOversold
VolatilityHigh, 62.9%/day
Key levels
$3.8252 week high+570.2%
$2.09200 day average+266.7%
$1.63100 day average+186.0%
$0.9950 day average+73.7%
$0.87Swing high (Oct 30)+52.6%
$0.7520 day average+31.6%
$0.62Pivot R1+8.8%
$0.59Pivot+3.5%
$0.57Last close
$0.5552 week low−3.5%
$0.53Pivot S1−7.0%
Indicators
RSI (14)
27.75
Oversold below 30
Oversold
MACD
-0.45
Below its signal line
Bearish
Stochastic
1.2
Near the bottom of its range
Oversold
ADX (14)
17.1
No clear trend
Williams %R
-99.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-99.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−72.1%
Change over 10 sessions
Bearish
ATR (14)
$0.36
Typical daily range, 62.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CNTB
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CNTB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow CNTB usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CNTB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CNTB is in one of them and how their past CNTB trades turned out.
Connect Biopharma is a biopharmaceutical company based in San Diego, California. It is developing rademikibart, an antibody designed to block a receptor involved in airway inflammation. The drug is in clinical trials for sudden worsening episodes of asthma and chronic obstructive pulmonary disease (COPD), which are lung conditions that make breathing difficult. The company's target market is patients with these diseases and the hospitals that treat them, although the drug is not yet approved for sale.